Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 11/20 | 0.65 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.43 |
| ▸ | MAOB | P27338 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HRH1 | P35367 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10226325 | 1.00 | HRH3 (0.65) | HRH3CXCR4SIGMAR1MAOBMAPT | |
| SCHEMBL30701394 | 1.00 | HRH3 (0.65) | HRH3CXCR4SIGMAR1MAOBMAPT | |
| SCHEMBL13293933 | 1.00 | HRH3 (0.65) | HRH3CXCR4SIGMAR1MAOBMAPT | |
| SCHEMBL17523768 | 1.00 | HRH3 (0.65) | HRH3CXCR4SIGMAR1MAOBMAPT | |
| SCHEMBL10032114 | 0.98 | HRH3 (0.61) | HRH3CXCR4SIGMAR1MAOBMAPT | |
| SCHEMBL13293936 | 0.98 | HRH3 (0.61) | HRH3CXCR4SIGMAR1MAOBMAPT | |
| SCHEMBL17523782 | 0.98 | HRH3 (0.61) | HRH3CXCR4SIGMAR1MAOBMAPT | |
| SCHEMBL13602667 | 0.98 | HRH3 (0.61) | HRH3CXCR4SIGMAR1MAOBMAPT | |
| SCHEMBL17523767 | 0.98 | HRH3 (0.61) | HRH3CXCR4SIGMAR1MAOBMAPT | |
| SCHEMBL13293934 | 0.98 | HRH3 (0.61) | HRH3CXCR4SIGMAR1MAOBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160039879-A1 | NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF | S&T GLOBAL INC. (US) | 2016-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160039879-A1 | NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF | FKBP1B, MALT1, FKBP5 | HRH3 4805/4885CXCR4 2243/4885SIGMAR1 3999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.